UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): March 7, 2016
BIO-PATH HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-36333 | 87-0652870 |
(State or other jurisdiction of incorporation)
|
(Commission File Number) | (IRS Employer Identification No.) |
4710 Bellaire Boulevard, Suite 210, Bellaire, Texas | 77401 |
(Address of principal executive offices) | (Zip Code) |
(832) 742-1357
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01 Regulation FD Disclosure.
On March 7, 2016, Bio-Path Holdings, Inc. (the “Company”) issued a press release titled, “Bio-Path Holdings to Present at the 28th Annual ROTH Conference.” A copy of such press release is attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit | |
Number | Description |
99.1 | Press Release dated March 7, 2016 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BIO-PATH HOLDINGS, Inc. | |||
Dated: March 7, 2016 | By: | /s/ Peter H. Nielsen | |
Peter H. Nielsen | |||
President and Chief Executive Officer |
EXHIBIT INDEX
Exhibit | |
Number | Description |
99.1 | Press Release dated March 7, 2016 |
Exhibit 99.1
Bio-Path Holdings to Present at the 28th Annual ROTH Conference
HOUSTON—March 7, 2016 – Bio-Path Holdings, Inc., (NASDAQ: BPTH) (“Bio-Path”), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter Nielsen, President and Chief Executive Officer, will deliver a company overview at the 28th Annual ROTH Conference in Dana Point, California on Monday, March 14 at 4:30 p.m. Pacific Time (1:30 p.m. Eastern Time).
A webcast of Mr. Nielsen’s presentation will be available at http://wsw.com/webcast/roth30/register.aspx?conf=roth30&page=bpth&url=http://wsw.com/webcast/roth30/bpth/index.aspx for 90 days following the live presentation.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company focused on developing therapeutic products utilizing DNAbilize™, its proprietary liposomal delivery and antisense technology, to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path’s lead product candidate, BP1001 (Liposomal Grb2 antisense), is in a Phase II study for blood cancers and in preclinical studies for triple negative and inflammatory breast cancers. Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors.
For more information, please visit the Company's website at http://www.biopathholdings.com.
Forward-Looking Statements
Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including Bio-Path’s ability to raise needed additional capital on a timely basis in order for it to continue its operations, have success in the clinical development of its technologies, the timing of enrollment and release of data in such clinical studies and the accuracy of such data, limited patient populations of early stage clinical studies and the possibility that results from later stage clinical trials with much larger patient populations may not be consistent with earlier stage clinical trials, and such other risks which are identified in the Company's most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Bio-Path Holdings or at www.sec.gov. Bio-Path disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
# # #
Contact Information:
Investors
Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369
Steve Silver
Rx Communications Group, LLC
917-322-2569
ssilver@rxir.com
Media
Tony Plohoros
6 Degrees
908-591-2839
tplohoros@6degreespr.com